Featured Research

from universities, journals, and other organizations

Experimental Anti-cancer Drug Reduces Tumor Growth And Tumor Volume In Mice

Date:
February 10, 2008
Source:
Centre for Synthesis and Chemical Biology
Summary:
Significant pre-clinical results on the anti-tumor activity of Titanocene Y on human breast tumors and in a mouse model have just been published. In the mouse model, a decrease not only in tumor growth but also a reduction in tumor volume to around one-third was observed for the first time. In the human breast cancer, Titanocene Y showed cell death induction comparable to the widely-used chemotherapy drug Cisplatin.

Dr Matthias Tacke and his research team at the Centre for Synthesis and Chemical Biology and the School of Chemistry and Chemical Biology at University College Dublin have recently published highly significant preclinical results on the anti-tumour activity of Titanocene Y on human breast tumours and in a mouse model.

Related Articles


In the mouse model, a decrease not only in tumour growth but also a reduction in tumour volume to around one-third was observed for the first time. In the human breast cancer, Titanocene Y showed cell death induction comparable to the widely-used chemotherapy drug Cisplatin.

Dr Tacke's group has been working on anti-cancer drugs belonging to the titanocene family for five years. 25 novel compounds were initially synthesised in the lab, and were structurally identified and then biologically evaluated.

The most successful analogues so far, Titanocene X and Titanocene Y, have been shown in early in-vitro and ex-vitro experiments to target prostrate, cervix and renal cell cancers, as well as breast cancer cell lines. The researchers believe that titanocenes represent a novel series of promising antitumour agents.

According to Dr Tacke: "The successor molecule has been synthesised and has been shown to be 13 times more cytotoxic in vitro. Investigations of this candidate in the next mouse model are currently underway."

Journal reference: Beckhove, P., Oberschmidt, O., Hanauske, A. R., Pampillon, C., Schirrmacher, V., Sweeney, N. J., Strohfeldt, K., Tacke, M. Anti-Cancer Drugs 2007, 18: 311-315.


Story Source:

The above story is based on materials provided by Centre for Synthesis and Chemical Biology. Note: Materials may be edited for content and length.


Cite This Page:

Centre for Synthesis and Chemical Biology. "Experimental Anti-cancer Drug Reduces Tumor Growth And Tumor Volume In Mice." ScienceDaily. ScienceDaily, 10 February 2008. <www.sciencedaily.com/releases/2008/02/080206152424.htm>.
Centre for Synthesis and Chemical Biology. (2008, February 10). Experimental Anti-cancer Drug Reduces Tumor Growth And Tumor Volume In Mice. ScienceDaily. Retrieved March 3, 2015 from www.sciencedaily.com/releases/2008/02/080206152424.htm
Centre for Synthesis and Chemical Biology. "Experimental Anti-cancer Drug Reduces Tumor Growth And Tumor Volume In Mice." ScienceDaily. www.sciencedaily.com/releases/2008/02/080206152424.htm (accessed March 3, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Tuesday, March 3, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Treadmill Test Can Predict Chance Of Death Within A Decade

Treadmill Test Can Predict Chance Of Death Within A Decade

Newsy (Mar. 2, 2015) Johns Hopkins researchers analyzed 58,000 heart stress tests to come up with a formula that predicts a person&apos;s chances of dying in the next decade. Video provided by Newsy
Powered by NewsLook.com
Going Gluten-Free Could Get You A Tax Break

Going Gluten-Free Could Get You A Tax Break

Newsy (Mar. 2, 2015) If a doctor advises you to remove gluten from your diet, you could get a tax deduction on the amount you spend on gluten-free foods. Video provided by Newsy
Powered by NewsLook.com
GlaxoSmithKline and Novartis Try Swapping Success

GlaxoSmithKline and Novartis Try Swapping Success

Reuters - Business Video Online (Mar. 2, 2015) GlaxoSmithKline and Novartis have completed a series of asset swaps worth more than $20 billion. As Grace Pascoe reports they say the deal will reshape both drugmakers. Video provided by Reuters
Powered by NewsLook.com
How Can West Africa Rebuild After Ebola?

How Can West Africa Rebuild After Ebola?

Reuters - Business Video Online (Mar. 2, 2015) How best to rebuild the three West African countries struggling with Ebola will be discussed in Brussels this week. As Hayley Platt reports Sierra Leone has the toughest job ahead - its once thriving economy has been ravaged by the disease. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins